• 1
    Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80: 21930.
  • 2
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Maincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 1998;4: 3217.
  • 3
    Jaeger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jaeger D, et al. GM-CSF enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67: 5462.
  • 4
    Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1–restricted MAGE-3 epitope peptide with IFA in patients with resected high-risk melanoma. J Immunother 1999;5: 43140.
  • 5
    Scheibenbogen C, Schmittel A, Keilholz U, Allgäuer T, Hofmann U, Max R, et al. Phase II trial of vaccination with tyrosinase peptides and GM-CSF in melanoma. J Immunother 2000;23: 27581.
  • 6
    Lewis JJ, Janetzki S, Schaed S, Panageas C, Wang S, Williams L, et al. Evaluation of CD8+ T cell frequencies by the ELISPOT assay in healthy individuals and patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 2000;87: 3918.
  • 7
    Wang F, Bade E, Kuniyoshi C, Spears L, Jeffrey G, Marty V, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5: 275665.
  • 8
    Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999;163: 6292300.
  • 9
    Marincola FM. The multiple ways to tumor tolerance. J Immunother 1997;20: 1789.
  • 10
    Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74: 181273.
  • 11
    Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000;21: 45564.
  • 12
    Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16: 291320.
  • 13
    Skipper J, Hendrickson R, Gulden P, Brichard V, Van Pel A, Chen Y, et al. An HLA-A2–restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183: 52734.
  • 14
    Kang X, Kawakami Y, El-Gamil M, Wang R, Sakaguchi K, Yanelli JR, et al. Identification of a tyrosinase epitope recognized by HLA-A24–restricted, tumor-infiltrating lymphocytes. J Immunol 1995;155: 13438.
  • 15
    Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerrotini JC, et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromium release assay: a four-centre comparative study. J Immunol Methods 2000;244: 819.
  • 16
    Letsch A, Keilholz U, Schadendorf D, Nagorsen D, Schmittel A, Thiel E, Scheibenbogen C. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int J Cancer 2000;87: 65964.
  • 17
    Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Thiel E, Scheibenbogen C. Flow cytometric determination of intracellular or secreted IFNγ for quantitation of antigen-reactive T cells. J Immunol Methods 2001;251: 1018.
  • 18
    Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401: 70812.
  • 19
    Max N, Wolf K, Spike B, Thiel E, Keilholz U. Nested quantitative real time PCR for detection of occult tumor cells. Recent Results Cancer Res 2001;158: 2531.
  • 20
    Delp K, Momburg F, Hilmes C, Huber C, Seliger B. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Bone Marrow Transplant 2000;25: S8895.
  • 21
    Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Störkel S, Kiessling R. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1–restricted cytotoxic T lymphocytes. Int J Cancer 2000;87: 34959.
  • 22
    Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al. Effects of IL-12 on the immune response to a multipeptide vaccine for resected melanoma. J Clin Oncol 2001;19: 383647.
  • 23
    Slingluff C, Yamshchikov GV, Neese P, Galavotti H, Eastham S, Engelhard V, et al. Phase I trial of a melanoma vaccine with gp100 280–288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcome. Clin Cancer Res 2001;7: 301224.
  • 24
    Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients vaccinated with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001;61: 64518
  • 25
    Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol 2001;13: 62532.
  • 26
    Nielsen MB, Monsurro V, Migueles SA, Wang E, Perez-Diez A, Lee KH, et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol 2000;165: 228796.
  • 27
    Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Roder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000;165: 34926.
  • 28
    Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66: 4706.